Patent Bill Aims For Trolls, But Will It Snare Rx Firms Instead?
Executive Summary
Rep. Bob Goodlatte’s Innovation Act would delay discovery, require more information to file suits, which could increase the time and expense of pursuing infringement cases.
You may also be interested in...
Drug Firms Ask Senate For Narrow Patent Troll Bill
“One-size-fits-all” patent troll bill will harm innovators, Johnson & Johnson’s chief IP counsel tells Senate hearing.
Patent Troll Bill Clears House; Provisions Problematic For PhRMA Remain
Amendments make things a little better for drug firms as attention now shifts to the Senate version.
Generic Manufacturers May Gain Edge In New Patent Challenge Procedure At PTO
Apotex’s challenge of Alcon’s Vigamox patent put PTO’s new inter partes review proceeding in the spotlight; 45 petitions have been filed in the biopharma sector.